SFXN3 and Parkinson disease: We demonstrate that experimental manipulation of SFXN3 impacts on expression levels of several known regulators of synaptic degeneration (including cysteine string protein α (CSPα) and caspase‐3) and controls expression of the constituents of established molecular neurodegeneration pathways associated with neurodegenerative diseases including PD and AD.